Prothena Corporation plc Stock News

Prothena (PRTA) makes good progress with its AD candidates. However, AD is a challenging space and the successful development of these candidates is crucial.

Prothena (PRTA) delivers earnings of 38 cents in the third quarter, driven by the license and option exercise fee paid by BMY.

Prothena (PRTA) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of a loss of $0.26 per share. This compares to loss of $0.97 per share a year ago.

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that it will report its third quarter and first nine months of 2023 financial results on November 2, 2023.

Biogen stock tumbled Thursday — pulling Prothena stock down — on mixed test results for an updated version of its Alzheimer's treatment.

Let us look at some biotech stocks, AMGN, BIIB, GSK, PRTA and VRTX, which are poised to beat on third-quarter earnings.

Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ro

Shares of Prothena Corporation (NASDAQ:PRTA) added almost 25% on rumours the biotechnology firm is exploring a sale ahead of the release of key data from its highly anticipated Phase 1 Alzheimer's Dis

Biotech firm Prothena Corp is preparing for a potential sale, Bloomberg News reported on Monday, citing people with knowledge of the matter.

Prothena Corporation is a protein dysregulation specialist with a focus on developing drugs for Alzheimer's disease. The company's lead candidate, PRX012, is an amyloid clearing drug that is currently

Prothena (PRTA) gains a massive 88.7% in 12 months on pipeline progress with its AD candidates.

Prothena (PRTA) reports a wider-than-expected loss in the second quarter. The company makes considerable pipeline progress and updates 2023 bottom-line guidance.

Prothena (PRTA) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to loss of $0.88 per share a year ago.

Prothena (PRTA) will receive $55 million from Bristol Myers Squibb for an exclusive worldwide license to PRX005, designed for the potential treatment of Alzheimer's disease.

Prothena's recent collaboration with Walgreens is expected to drive recruitment for Prothena's ongoing ASCENT-2 safety and tolerability trial of PRX012. PRX012, an anti-amyloid beta antibody, has show